<DOC>
	<DOCNO>NCT00566189</DOCNO>
	<brief_summary>Bariatric surgery lead remission type 2 diabetes morbid obese patient 80 % ( Roux-en-Y gastric bypass ) 90 % ( biliopancreatic diversion duodenal switch ) case . The current consensus support bariatric surgical treatment diabetic patient BMI low 35kg/m2 question low body mass patient might benefit surgery well . This study propose describe effect Roux-en-Y gastric bypass mild obese ( BMI 30-35 ) human volunteer incretins , insulin production sensitivity clinical ( diabetic chronic complication ) metabolic impact .</brief_summary>
	<brief_title>New Frontiers Bariatric Surgical Procedures : Classical Bypass Type-2 Diabetic Patients With Obesity Grade I</brief_title>
	<detailed_description>Bariatric surgery lead remission type 2 diabetes morbid obese patient 80 % ( Roux-en-Y gastric bypass ) 90 % ( biliopancreatic diversion duodenal switch ) case ; remainder achieve good glycemic control , even regain weight . The current consensus support bariatric surgical treatment diabetic patient BMI low 35kg/m2 question low body mass patient might benefit surgery well . Actually , many clinical researcher worldwide would consider low limit BMI 30kg/m2 , i.e. , grade obesity . This study propose describe effect Roux-en-Y gastric bypass ( Fobi-Capella technique , adapt create large gastric pouch , 80ml ) mild obese ( BMI 30-35 ) human volunteer incretins , insulin production sensitivity clinical ( diabetic chronic complication ) metabolic impact .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<criteria>Obesity grade I ( BMI 3034,9 ) Weight variance le 5 % last 3 month . Previous diagnosis diabetes type 2 . Insulin requirement , alone along oral agent Capacity understand procedure study . To agree voluntarily participate study , sign informed consent . Positive AntiGAD antibody Laboratorial signal probable failure insulin production , i. e. , seric peptide C lesser 1 ng/mL . History hepatic disease like cirrhosis chronic active hepatitis . Kidney dysfunction ( creatinine &gt; 1,4 mg/dl woman &gt; 1,5 mg/dl men ) . Hepatic dysfunction : aspartate aminotransferase alanine aminotransferase 3x upper normal limit . Recent history neoplasia ( &lt; 5 year ) . Use oral injectable corticosteroid consecutive 14 day last three month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>diabetes mellitus , type 2</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Intra-Abdominal Fat</keyword>
	<keyword>Omentum</keyword>
	<keyword>duodenal exclusion</keyword>
	<keyword>bariatric surgery</keyword>
	<keyword>Glucagon-Like Peptide 1</keyword>
	<keyword>Gastric Inhibitory Polypeptide</keyword>
	<keyword>insulin</keyword>
	<keyword>glucagon</keyword>
	<keyword>ghrelin</keyword>
	<keyword>adiponectin</keyword>
	<keyword>Cytokines</keyword>
</DOC>